Trastuzumab Emtansine 100 mg injection

About Trastuzumab Emtansine 100 mg injection

Discription to Ujvira 100mg Injection

Ujvira 100mg Injection is a targeted therapy containing the active constituent trastuzumab emtansine. The U.S. Food and Drug Administration (FDA) approved trastuzumab emtansine on February 22, 2013, for treating patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and chemotherapy. This medication is not recommended for adolescents and children under 18. Before taking this medicine, it is vital to inform your doctor if you have any blood clot disorders, liver disorders, or allergies.

Uses of Ujvira 100mg Injection

Ujvira 100mg Injection is indicated for its use in the following conditions:

• Advanced and metastatic breast cancer

Therapeutic Effects of Ujvira 100mg Injection

Trastuzumab binds selectively to the HER2 receptors on breast cancer cells' surface, blocks them from receiving growth signals, and stops the cancer cell's growth. DM1 becomes active once the drug enters the cancer cells and helps stop cancer cell growth.